These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8643177)

  • 21. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
    Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H
    Panminerva Med; 2003 Mar; 45(1):59-62. PubMed ID: 12682621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between erythropoietin requirements and antihypertensive agents.
    Yano S; Suzuki K; Iwamoto M; Urushidani Y; Yokogi H; Kusakari M; Aoki A; Sumi M; Kitamura K; Sanematsu H; Gohbara M; Imamura S; Sugimoto T
    Nephron Clin Pract; 2008; 109(1):c33-9. PubMed ID: 18506108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dosage of erythropoietin in children treated with hemodialysis and continuous ambulatory peritoneal dialysis].
    Sieniawska M; Roszkowska-Blaim M
    Pediatr Pol; 1995 Dec; 70(12):1023-8. PubMed ID: 8649941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.
    Schwenk MH; Jumani AQ; Rosenberg CR; Kulogowski JE; Charytan C; Spinowitz BS
    Pharmacotherapy; 1998; 18(3):627-30. PubMed ID: 9620114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased coated-platelet levels in chronic haemodialysis patients.
    Valaydon ZS; Lee P; Dale GL; Januszewski AS; Rowley KG; Nandurkar H; Karschimkus C; Best JD; Lyons TJ; Jenkins AJ
    Nephrology (Carlton); 2009 Apr; 14(2):148-54. PubMed ID: 19076292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphocyte subset counts in continuous ambulatory peritoneal dialysis patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors.
    Grzegorzewska AE; Leander M
    Adv Perit Dial; 2002; 18():6-11. PubMed ID: 12402577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
    Hess E; Sperschneider H; Stein G
    Nephrol Dial Transplant; 1996 Apr; 11(4):749-751. PubMed ID: 8671881
    [No Abstract]   [Full Text] [Related]  

  • 30. [The optimization of the treatment and timing of the intervention by a nephrologist in pre-dialytic chronic renal insufficiency].
    Sirignano C; D'Urso P; Di Iorio BR;
    G Ital Nefrol; 2003; 20(2):133-8. PubMed ID: 12746798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of captopril-bound Fe by end-stage renal failure patients during hemodialysis.
    Averbukh Z; Berman S; Kishinevsky E; Feldman L; Cohn M; Rapoport M; Galperin E; Dishi V; Weissgarten J
    J Nephrol; 2004; 17(1):101-6. PubMed ID: 15151265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary hyperaldosteronism in a patient with end-stage renal disease.
    Kazory A; Weiner ID
    Nephrol Dial Transplant; 2007 Mar; 22(3):917-9. PubMed ID: 17127694
    [No Abstract]   [Full Text] [Related]  

  • 33. Managing progressive renal disease before dialysis.
    Barrett BJ
    Can Fam Physician; 1999 Apr; 45():977-84. PubMed ID: 10216796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin can be administered during dialysis. A kinetic analysis.
    Petersen J; Kang MS; Hays MT
    ASAIO J; 1996; 42(1):27-33. PubMed ID: 8808454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of an ambulatory program devoted to chronic renal insufficiency on the reduction of mobidity and hospitalization among patients at the beginning of dialysis treatment].
    Malberti F; Ravani P
    G Ital Nefrol; 2003; 20(2):127-32. PubMed ID: 12746797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.
    Le Meur Y; Lorgeot V; Comte L; Szelag JC; Aldigier JC; Leroux-Robert C; Praloran V
    Am J Kidney Dis; 2001 Sep; 38(3):510-7. PubMed ID: 11532682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients.
    Altun B; Erdem Y; Haznedaroğlu I; Gürsoy M; Yasavul U; Turgan C; Cağlar S; Kirazli S
    Nephrol Dial Transplant; 1995 Nov; 10(11):2164. PubMed ID: 8643199
    [No Abstract]   [Full Text] [Related]  

  • 38. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
    de Francisco AL; Sulowicz W; Klinger M; Niemczyk S; Vargemezis V; Metivier F; Dougherty FC; Oguey D;
    Int J Clin Pract; 2006 Dec; 60(12):1687-96. PubMed ID: 17109676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.
    Locatelli F; Andrulli S; Memoli B; Maffei C; Del Vecchio L; Aterini S; De Simone W; Mandalari A; Brunori G; Amato M; Cianciaruso B; Zoccali C
    Nephrol Dial Transplant; 2006 Apr; 21(4):991-8. PubMed ID: 16384825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute effect of trandolapril on serum erythropoietin in uremic and hypertensive patients.
    Akpolat T; Gumus T; Bedir A; Adam B
    J Nephrol; 1998; 11(2):94-7. PubMed ID: 9589381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.